Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Table 1

Participant characteristics.

Variables	Total ()
Age (years)	67.5 (53.5, 69.8)
Female sex ()	7
BMI (kg/m^2)	26.8 (23.7, 27.9)
Diabetes duration (years)	3.5 (0.5, 15.8)
FPG (mg/dL)	117.0 (102.8, 179.5)
HbA1c (%)
CPR (ng/mL)
CPI (ng/mL per mg/dL)
ΔCPR (ng/mL)
UACR (mg/gCr)	11.9 (4.2, 41.8)
eGFR (mL/min/1.73m^2)
IDeg (unit/day)	7 (4.0, 9.5)
IDegLira after switching (dose/day)	7 (4.0, 9.5)
The proportion of oral hypoglycemic agent
Metformin (%)	8 (66.7)
Alpha glucosidase inhibitors (%)	1 (8.3)
Glinides (%)	1 (8.3)
SGLT2 inhibitors (%)	3 (25.0)
Bolus insulin (%)	1 (8.3)
Total daily dose (units)	14

Values are expressed as or median (interquartile range). BMI: body mass index; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; CPR: C-peptide; CPI: C-peptide index; ΔCPR: C-peptide immunoreactivity after glucagon stimulation; UACR: urine albumin to creatinine ratio; eGFR: estimated glomerular filtration rate; IDeg: insulin degludec before switching; IDegLira: insulin degludec/liraglutide after switching; SGLT2: sodium-glucose cotransporter 2.